华康生物医学2023年报

(incorporated in the Cayman Islands with limited liability)Stock Code: 8622 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OFHONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM GEM has been positioned as a market designed to accommodate small and mid-sized companiesto which a higher investment risk may be attached than other companies listed on the StockExchange. Prospective investors should be aware of the potential risks of investing in suchcompanies and should make the decision to invest only after due and careful consideration. Given that the companies listed on GEM are generally small and mid-sized companies, there isarisk that securities traded on GEM may be more susceptible to high market volatility thansecurities traded on the Main Board of the Stock Exchange and no assurance is given that therewill be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for thecontents of this report (“Report”), make no representation as to its accuracy or completeness andexpressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon thewhole or any part of the contents of the Report. This Report, for which the directors (the “Directors”) of Huakang Biomedical Holdings Company Limited(the “Company”, and together with its subsidiaries, the “Group”, “we” or “our”) collectively andindividually accept full responsibility, includes particulars given in compliance with the Rules Governing theListing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of givinginformation with regard to the Group. The Directors, having made all reasonable enquiries, confirm that tothe best of their knowledge and belief, the information contained in this Report is accurate and completein all material respects and not misleading or deceptive, and there are no other matters the omission ofwhich would make any statement herein or this Report misleading. GEM GEMGEMGEM GEMGEM Corporate Information3Chairman’s Statement4Management Discussion and Analysis6Biographies of Directors andSenior Management20Corporate Governance Report27Environmental, Social andGovernance Report53Report of the Directors91Independent Auditor’s Report113Consolidated Statement ofProfit or Loss andOther Comprehensive Income124Consolidated Statement ofFinancial Position125Consolidated Statement ofChanges in Equity127Consolidated Statement of Cash Flows129Notes to theConsolidated Financial Statements131Financial Summary244 CORPORATE INFORMATION Company Secretary Principal Place of Businessin the PRC Board of Directors Mr. Chau Lai Ki Mr. Zhang Shuguang(Chairman)Mr. Zhang ChunguangMr. Poon Lai Yin MichaelMr. He Jiaming 1–3/F and 5/F, Building D,Shenzhen Junxuan,No. 16 Yinkui Road,Kui Xin Community,Kui Chong Office,Dapeng New District,Shenzhen,The PRC16D Authorised Representatives(for the purposes ofthe GEM Listing Rules)GEM Mr. Zhang ShuguangMr. Poon Lai Yin Michael Independent Non-executiveDirectors Dr. Chow Kwok Fai JosephDr. Cheng Faat Ting GaryMr. Chan Kin SangMs. Chow Ching Man(appointed on 2 August 2023) Compliance Officer Mr. Poon Lai Yin Michael Legal Advisers as toHong Kong laws Principal Share Registrarand Transfer Office in theCayman Islands Tung, Ng, Tse & LamSolicitors Audit Committee Conyers Trust Company(Cayman) LimitedCricket Square,Hutchins Drive,P.O. Box 2681,Grand Cayman KY1-1111,Cayman Islands Auditor Dr. Cheng Faat Ting Gary(Chairman)Dr. Chow Kwok Fai JosephMr. Chan Kin SangMs. Chow Ching Man(appointed on 2 August 2023) Mazars CPA Limited Registered Office Hong Kong ShareRegistrar and TransferBranch Office Cricket Square,Hutchins Drive,P.O. Box 2681,Grand Cayman, KY1-1111,Cayman Islands Tricor Investor Services Limited17/F, Far East Financial Centre,16 Harcourt Road,Hong Kong1617 Remuneration Committee Principal Place of Businessin Hong Kong Dr. Cheng Faat Ting Gary(Chairman)Dr. Chow Kwok Fai JosephMr. Zhang Chunguang Room 04, 9 Floor,Kimberley House,35–35A Kimberley Road,Tsim Sha Tsui,Kowloon,Hong Kong35–35A904 Company’s Websites http://www.huakangbiomedical.com Nomination Committee Stock Code8622 Mr. Zhang Shuguang(Chairman)Dr. Chow Kwok Fai JosephMr. Chan Kin SangMs. Chow Ching Man(appointed on 2 August 2023) CHAIRMAN’S STATEMENT Dear Shareholders, On behalf of the board of directors (the “Board”) ofHuakang Biomedical Holdings Company Limited, I ampleased to present the Group’s annual results for the yearended 31 December 2023. (COVID-19)12.43‰6.39‰85.4% During the first half year of 2023, the economy andbusiness activities of the People’s Republic of China (the“PRC”) have still to be disrupted by the novel coronavirus(COVID-19) epidemic (the “Epidemic”). Despite thedifficulties arising from the Epidemic, and the birth rateof the PRC has fallen for six consecutive years from12.43‰for 2017 to 6.39‰for 2023, according to thestatistics published by the National Bureau o